Innovations rapidly and equitably to people

Breakthroughs in healthcare are meaningful only when they reach the people in need of therapy. The value of innovative medicines and vaccines is only realized through rapid and equal access to them.

It is vital to eliminate delays and regional differences so that each wellbeing services county has equal access to the novel therapies. Moreover, Finland has to intervene with the worrisome trend whereby Finnish patients have access to fewer pharmaceuticals compared to those available in other European countries.

Rapid and equal access to medicines and vaccines calls for an open and efficient assessment system. The harmonization of HTA processes improves predictability, quality of treatments and efficient use of resources.

An efficient pharmaceutical assessment system can also steer investment decisions. To attract investments, Finland must provide a clear and efficient route to the market so that the medicines are available to the patients without delay.